{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T06:21:31Z","timestamp":1773642091662,"version":"3.50.1"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T00:00:00Z","timestamp":1773619200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) is a rare sub-type of Hodgkin lymphoma (HL). Due to its rarity, the standard of care for these patients remains poorly defined. Our cohort aimed to evaluate the outcomes of pediatric NLPHL patients treated with the R-CHOP regimen throughout 8 years\u2019 single center experience.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective cohort study including pediatric patients aged &amp;lt;18 years diagnosed with NLPHL and treated at the Children Cancer Hospital Egypt, between July 2014 and June 2022.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In total, 66 patients were included. Twelve patients (18%) with stage IA underwent surgical excision alone. Four of these patients experienced disease progression but achieved a complete response after receiving R-CHOP. Fifty-four patients received R-CHOP as first-line therapy, with early-stage disease received 3\u20134 cycles, while those with advanced-stage disease received 6 cycles. For this group, the 5-year overall (OS) and event free survival (EFS) were 100% and 91.5%, respectively. The 5-year EFS was not significantly affected by the variant histology pattern among patients received R-CHOP. Patients with stage 3 peripheral disease without risk factors demonstrated outcomes comparable to those with early-stage disease and no risk factors, achieving an excellent 5-year EFS rate of 100%. No significant toxicity was reported, except for grade 3\u20134 neutropenia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>R-CHOP is an effective and well-tolerated regimen for treating pediatric NLPHL, demonstrating high OS and EFS rates. Patients with early stage disease achieved particularly favorable outcomes, supporting consideration of treatment de-escalation in this subgroup.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1740063","type":"journal-article","created":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T05:23:31Z","timestamp":1773638611000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Promising outcomes of R-CHOP therapy in pediatric nodular lymphocyte-predominant Hodgkin lymphoma: perspectives from a rare subtype"],"prefix":"10.3389","volume":"16","author":[{"given":"Nesreen","family":"Ali","sequence":"first","affiliation":[{"name":"Department of Pediatric Oncology, National Cancer Institute, Cairo University","place":["Cairo, Egypt"]},{"name":"Department of Pediatric Oncology, Children\u2019s Cancer Hospital Egypt 57357","place":["Cairo, Egypt"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eman","family":"Khorshed","sequence":"additional","affiliation":[{"name":"Department of Pathology, National Cancer Institute, Cairo University","place":["Cairo, Egypt"]},{"name":"Department of Pathology, Children\u2019s Cancer Hospital Egypt 57357","place":["Cairo, Egypt"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed S.","family":"Zaghloul","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, National Cancer Institute, Cairo University","place":["Cairo, Egypt"]},{"name":"Department of Radiation Oncology, Children\u2019s Cancer Hospital Egypt 57357","place":["Cairo, Egypt"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maha","family":"Mehsen","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, National Cancer Institute, Cairo University","place":["Cairo, Egypt"]},{"name":"Department of Nuclear Medicine, Children\u2019s Cancer Hospital Egypt","place":["Cairo, Egypt"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Badawy","sequence":"additional","affiliation":[{"name":"Department of Clinical Research, Children\u2019s Cancer Hospital Egypt 57357","place":["Cairo, Egypt"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Walaa","family":"Elsayed","sequence":"additional","affiliation":[{"name":"Department of Pediatric Oncology, National Cancer Institute, Cairo University","place":["Cairo, Egypt"]},{"name":"Department of Pediatric Oncology, Children\u2019s Cancer Hospital Egypt 57357","place":["Cairo, Egypt"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-12-541078","article-title":"Advanced-stage nodular lymphocyte predominant Hodgkin lymphoma compared with classical Hodgkin lymphoma: a matched pair outcome analysis","volume":"123","author":"Xing","year":"2014","journal-title":"Blood"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12055","article-title":"Nodular lymphocyte predominant Hodgkin lymphoma in children and adolescents- a comprehensive review of biology, clinical course and treatment options","volume":"159","author":"Shankar","year":"2012","journal-title":"Br J Haematol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18169","article-title":"Management of children and adults with all stages of nodular lymphocyte predominant Hodgkin lymphoma \u2014 All StAGEs: A consensus-based position paper from the Hodgkin lymphoma subgroup of the UK National Cancer Research Institute","volume":"197","author":"Shankar","year":"2022","journal-title":"Br J Haematol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j","article-title":"Nodular lymphocyte predominant Hodgkin lymphoma: pathology, clinical course and relation to T-cell\/histiocyte rich large B cell lymphoma","volume":"52","author":"Hartmann","year":"2020","journal-title":"Pathology"},{"key":"B5","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/bjh.15616","article-title":"Modern principles in the management of nodular lymphocyte-predominant Hodgkin lymphoma","volume":"184","author":"Spinner","year":"2019","journal-title":"Br J Haematol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"e30647","DOI":"10.1002\/pbc.30647","article-title":"Variant histology of pediatric nodular lymphocyte-predominant Hodgkin lymphoma with IgD and CD30 expression","volume":"70","author":"Ali","year":"2023","journal-title":"Pediatr Blood Cancer"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.11.8869","article-title":"Lymphocyte-predominant and classical Hodgkin\u2019s lymphoma: a comprehensive analysis from the German Hodgkin study group","volume":"26","author":"Nogov","year":"2008","journal-title":"J Clin Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1432650","article-title":"Exploring the complexity, treatment challenges, and outcomes in pediatric nodular lymphocyte predominant Hodgkin lymphoma: a perspective from a low\u2013 middle-income country","volume":"14","author":"Madney","year":"2024","journal-title":"Front Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1182\/blood","article-title":"Outcomes of nodular lymphocyte predominant hodgkin\u2019s lymphoma (NLPHL) patients treated with R-CHOP","volume":"116","author":"Fanale","year":"2010","journal-title":"Blood"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-02-766121","article-title":"Encouraging activity for R-CHOP in advanced stage nodular lymphocyte\u2013predominant Hodgkin lymphoma","volume":"130","author":"Fanale","year":"2017","journal-title":"Blood"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1097\/00000478-200310000-00007","article-title":"Characterization of variant patterns of nodular lymphocyte predominant hodgkin lymphoma with immunohistologic and clinical correlation","volume":"27","author":"Fan","year":"2003","journal-title":"Am J Surg Pathol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-07-515825","article-title":"The prognostic impact of variant histology in nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group (GHSG)","volume":"122","author":"Hartmann","year":"2013","journal-title":"Blood"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1989.7.11.1630","article-title":"Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin\u2019s disease: Cotswolds meeting","volume":"7","author":"Lister","year":"1989","journal-title":"J Clin Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-hodgkin lymphoma: The lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1182\/asheducation-2017.1.324","article-title":"Management of nodular lymphocyte-predominant Hodgkin lymphoma","volume":"31","author":"Eichenauer","year":"2013","journal-title":"Hematol Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2017.1.324","article-title":"Nodular lymphocyte-predominant Hodgkin lymphoma: a unique disease deserving unique management","volume":"2017","author":"Eichenauer","year":"2017","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.65.3469","article-title":"Minimal treatment of low-risk, pediatric lymphocyte-predominant Hodgkin lymphoma: a report from the Children\u2019s Oncology Group","volume":"34","author":"Appel","year":"2016","journal-title":"J Clin Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13540","article-title":"Childhood and Adolescent nodular lymphocyte predominant Hodgkin lymphoma- A review of clinical outcome based on the histological variants","volume":"171","author":"Shankar","year":"2015","journal-title":"Br J Haematol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22762","article-title":"Resection alone in 58 children with limited stage, lymphocyte-predominant Hodgkin lymphoma-experience from the European network group on pediatric Hodgkin lymphoma","volume":"110","author":"Mauz-K\u00f6rholz","year":"2007","journal-title":"Cancer"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2011.10.018","article-title":"Treatment outcome after low intensity chemotherapy [CVP] in children and adolescents with early stage nodular lymphocyte predominant Hodgkin\u2019s lymphoma\u2014 an Anglo-French collaborative report","volume":"48","author":"Shankar","year":"2012","journal-title":"Eur J Cancer"},{"key":"B21","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1200\/JCO.19.00986","article-title":"Long-term follow-up of patients with nodular lymphocyte-predominant hodgkin lymphoma treated in the HD7 to HD15 trials: A report from the German hodgkin study group","volume":"38","author":"Eichenauer","year":"2020","journal-title":"J Clin Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.60.4363","article-title":"Long-term course of patients with stage IA nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group","volume":"33","author":"Eichenauer","year":"2015","journal-title":"J Clin Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13081760","article-title":"Rituximab-containing risk-adapted treatment strategy in nodular lymphocyte predominant Hodgkin lymphoma: 7-years follow-up","volume":"13","author":"Pugliese","year":"2021","journal-title":"Cancers"},{"key":"B24","doi-asserted-by":"publisher","first-page":"e837","DOI":"10.1097\/HS9.0000000000000837","article-title":"Role of rituximab addition to first-line chemotherapy regimens in nodular lymphocyte-predominant hodgkin lymphoma: A study by fondazione italiana linfomi","volume":"7","author":"Gotti","year":"2023","journal-title":"HemaSphere"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14518","article-title":"Advanced stage nodular lymphocyte predominant Hodgkin lymphoma in children and adolescents: clinical characteristics and treatment outcome\u2013 a report from the SFCE & CCLG groups","volume":"177","author":"Shankar","year":"2017","journal-title":"Br J Haematol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-10-877761","article-title":"Active surveillance for nodular lymphocyte-predominant Hodgkin lymphoma","volume":"133","author":"Borchmann","year":"2019","journal-title":"Blood"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1097\/00043426-200205000-00010","article-title":"Lymphocyte-predominant Hodgkin disease in children","volume":"24","author":"Sandoval","year":"2002","journal-title":"J Pediatr Hematol Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13979","article-title":"Relapsed or poorly responsive nodular lymphocyte predominant Hodgkin lymphoma in children and adolescents \u2013a report from the United Kingdom\u2019s Children\u2019s cancer and Leukaemia study group","volume":"173","author":"Shankar","year":"2016","journal-title":"Br J Haematol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1111\/bjh.13842","article-title":"Guidelines for the investigation and management of nodular lymphocyte predominant Hodgkin lymphoma","volume":"172","author":"McKay","year":"2016","journal-title":"Br J Haematol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-025-02641-3","article-title":"Refining histopathological growth pattern-based risk group discrimination in nodular lymphocyte-predominant Hodgkin lymphoma: an analysis from the German Hodgkin Study Group","volume":"39","author":"Eichenauer","year":"2025","journal-title":"Leukemia"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1002\/hon.782","article-title":"Different histopathological subtypes of Hodgkin lymphoma show significantly different levels of FDG uptake","volume":"24","author":"Hutchings","year":"2006","journal-title":"Hematol Oncol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17281","article-title":"Outcome of relapsed and refractory nodular lymphocyte-predominant Hodgkin lymphoma: a north American analysis","volume":"192","author":"Strati","year":"2021","journal-title":"Br J Haematol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24927","article-title":"High dose chemotherapy and autologous stem cell transplantation in nodular lymphocyte-predominant Hodgkin lymphoma: a retrospective study by the European society for blood and marrow transplantation-lymphoma working party","volume":"93","author":"Akhtar","year":"2018","journal-title":"Am J Hematol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-02-836437","article-title":"Relapsed and refractory nodular lymphocyte-predominant Hodgkin lymphoma: an analysis from the German Hodgkin Study Group","volume":"132","author":"Eichenauer","year":"2018","journal-title":"Blood"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.24.9516","article-title":"Transformation to aggressive lymphoma in nodular lymphocyte-predominant Hodgkin\u2019s lymphoma","volume":"28","author":"Al-Mansour","year":"2010","journal-title":"J Clin Oncol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-08-665505","article-title":"Large B-cell transformation in nodular lymphocyte-predominant Hodgkin lymphoma: 40-year experience from a single institution","volume":"127","author":"Kenderian","year":"2016","journal-title":"Blood"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15133310","article-title":"Treatment of nodular lymphocyte-predominant Hodgkin lymphoma: Where do we stand? Where do we go","volume":"15","author":"Eichenauer","year":"2023","journal-title":"Cancer"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1740063\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T05:23:32Z","timestamp":1773638612000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1740063\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,16]]},"references-count":37,"alternative-id":["10.3389\/fonc.2026.1740063"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1740063","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,16]]},"article-number":"1740063"}}